Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Brain morphology changes in a remitted patient with late-onset, drug-naïve, non-psychotic major depressive disorder after amisulpride monotherapy.

Hou YC, Lai CH.

J Neuropsychiatry Clin Neurosci. 2013 Spring;25(2):E59-60. doi: 10.1176/appi.neuropsych.12050130. No abstract available.

PMID:
23686069
2.

Aripiprazole monotherapy-related gray-matter growth in a patient with first-episode drug-naïve non-psychotic major depressive disorder.

Lai CH.

J Neuropsychiatry Clin Neurosci. 2012 Summer;24(3):E49-50. doi: 10.1176/appi.neuropsych.11080198. No abstract available.

PMID:
23037685
3.

Combination therapy with amisulpride and antidepressants: clinical observations in case series of elderly patients with psychotic depression.

Politis AM, Papadimitriou GN, Theleritis CG, Psarros C, Soldatos CR.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul 1;32(5):1227-30. doi: 10.1016/j.pnpbp.2008.03.011. Epub 2008 Mar 25.

PMID:
18442877
4.

Should adjunctive antipsychotic treatment be continued in remitted patients with depression?

Uchida H, Suzuki T, Watanabe K, Kashima H.

Psychiatry Clin Neurosci. 2009 Feb;63(1):126. doi: 10.1111/j.1440-1819.2008.01897.x. No abstract available.

5.

Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis.

Psarros C, Theleritis CG, Paparrigopoulos TJ, Politis AM, Papadimitriou GN.

Int J Geriatr Psychiatry. 2009 May;24(5):518-22. doi: 10.1002/gps.2146.

PMID:
19072747
6.

Successful treatment of atypical depression with amisulpride: a case report.

Agarwal SM, Rao NP, Venkatasubramanian G, Behere RV, Varambally S, Gangadhar BN.

Asian J Psychiatr. 2012 Dec;5(4):362. doi: 10.1016/j.ajp.2011.12.005. Epub 2012 Jan 21. No abstract available.

PMID:
23174449
7.

Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy.

Lerner V, Bergman J, Borokhov A, Loewenthal U, Miodownik C.

Clin Neuropharmacol. 2005 Mar-Apr;28(2):66-71.

PMID:
15795548
8.

[Amisulpride: a treatment option for psychotic disorders soon to be available in the Netherlands].

Vinkers CH, Sommer IE.

Tijdschr Psychiatr. 2015;57(11):830-4. Review. Dutch.

9.

Clozapine with amisulpride for refractory schizophrenia.

Agelink MW, Kavuk I, Ak I.

Am J Psychiatry. 2004 May;161(5):924-5. No abstract available.

PMID:
15121665
10.

Successful treatment with amisulpride for poststroke psychosis.

Chen JH, Tzeng NS.

J Neuropsychiatry Clin Neurosci. 2010 Summer;22(3):352.e1. doi: 10.1176/appi.neuropsych.22.3.352.e1. No abstract available.

PMID:
20686144
11.

Amisulpride-induced mania with interictal psychosis.

Bakhla AK, Goyal N, Nizamie SH.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13;33(8):1572-3. doi: 10.1016/j.pnpbp.2009.09.010. Epub 2009 Sep 17. No abstract available.

PMID:
19766159
12.

Successful treatment of Tourette's disorder with amisulpride.

Fountoulakis KN, Iacovides A, St Kaprinis G.

Ann Pharmacother. 2004 May;38(5):901. Epub 2004 Mar 9. No abstract available.

PMID:
15010520
13.

Amisulpride treatment of somatoform disorders: not just chronic fatigue.

Goswami K, Saddichha S, Chaturvedi SK.

Am J Ther. 2014 Mar-Apr;21(2):e48-9. doi: 10.1097/MJT.0b013e3182383c78.

PMID:
23011165
14.

Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient.

Papadimitriou GN, Theleritis CG, Dikeos DG, Psarros CJ, Soldatos CR.

Int Clin Psychopharmacol. 2006 May;21(3):181-4.

PMID:
16528141
15.

Amisulpride monotherapy in a patient with clozapine-resistant schizophrenia.

Pehlivanidis A, Spyropoulou AC, Tourkantonis A, Papadimitriou GN.

Clin Neuropharmacol. 2010 May;33(3):168. doi: 10.1097/WNF.0b013e3181dc4e3d. No abstract available.

PMID:
20502137
16.

Amisulpride monotherapy may be a choice of maintenance treatment for patients with both bipolar I disorder and metabolic syndrome.

Hong CC, Chen CK, Yeh TC, Chu CS, Chen TY.

Aust N Z J Psychiatry. 2015 Aug;49(8):757-8. doi: 10.1177/0004867415577438. Epub 2015 Mar 18. No abstract available.

PMID:
25788497
17.

Improvement of amisulpride-induced extrapyramidal symptoms with quetiapine.

Jagadheesan K, Muirhead D.

Aust N Z J Psychiatry. 2004 Jul;38(7):560. No abstract available.

PMID:
15255830
18.

Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study.

Lin CH, Wang FC, Lin SC, Huang YH, Chen CC, Lane HY.

Int Clin Psychopharmacol. 2013 Sep;28(5):267-74. doi: 10.1097/YIC.0b013e3283633a83.

PMID:
23778382
19.

Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study.

Molina JD, Lerma-Carrillo I, Leonor M, Pascual F, Blasco-Fontecilla H, González-Parra S, López-Muñoz F, Alamo C.

Clin Neuropharmacol. 2009 Jan-Feb;32(1):10-5. doi: 10.1097/WNF.0B013E3181672213.

PMID:
18978498
20.

Plasma amisulpride levels in schizophrenia or schizoaffective disorder.

Bergemann N, Kopitz J, Kress KR, Frick A.

Eur Neuropsychopharmacol. 2004 May;14(3):245-50.

PMID:
15056484

Supplemental Content

Support Center